JP2022500410A5 - - Google Patents
Info
- Publication number
- JP2022500410A5 JP2022500410A5 JP2021513868A JP2021513868A JP2022500410A5 JP 2022500410 A5 JP2022500410 A5 JP 2022500410A5 JP 2021513868 A JP2021513868 A JP 2021513868A JP 2021513868 A JP2021513868 A JP 2021513868A JP 2022500410 A5 JP2022500410 A5 JP 2022500410A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antagonist
- heavy chain
- light chain
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862730772P | 2018-09-13 | 2018-09-13 | |
| US62/730,772 | 2018-09-13 | ||
| US201862755844P | 2018-11-05 | 2018-11-05 | |
| US62/755,844 | 2018-11-05 | ||
| PCT/US2019/050122 WO2020055702A1 (en) | 2018-09-13 | 2019-09-09 | Combination of pd-1 antagonist and lag3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022500410A JP2022500410A (ja) | 2022-01-04 |
| JP2022500410A5 true JP2022500410A5 (cg-RX-API-DMAC7.html) | 2022-09-01 |
| JP7470105B2 JP7470105B2 (ja) | 2024-04-17 |
Family
ID=69776882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021513868A Active JP7470105B2 (ja) | 2018-09-13 | 2019-09-09 | 非マイクロサテライト高不安定性/ミスマッチ修復の良好な結腸直腸がんを処置するためのpd-1アンタゴニストおよびlag3アンタゴニストの組み合わせ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210317214A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3849606A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7470105B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019337547A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3111066A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020055702A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2831084T3 (es) | 2016-06-10 | 2021-06-07 | Vitae Pharmaceuticals Inc | Inhibidores de la interacción menina-MLL |
| WO2020096917A1 (en) * | 2018-11-05 | 2020-05-14 | Merck Sharp & Dohme Corp. | Dosing regimen of anti-lag3 antibody and combination therapy with anti-pd-1 antibody for treating cancer |
| IL297039A (en) | 2020-04-07 | 2022-12-01 | Syndax Pharmaceuticals Inc | Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof |
| CA3196496A1 (en) | 2020-10-23 | 2022-04-28 | Laurence David TOMS | Lag-3 antagonist therapy for lung cancer |
| AR125866A1 (es) | 2021-05-14 | 2023-08-23 | Syndax Pharmaceuticals Inc | Inhibidores de la interacción de menina-mll |
| KR20240153583A (ko) * | 2022-02-25 | 2024-10-23 | 브리스톨-마이어스 스큅 컴퍼니 | 결장직장암종에 대한 병용 요법 |
| CN120514709A (zh) * | 2022-05-09 | 2025-08-22 | 赛达克斯制药股份有限公司 | 用于治疗癌症的menin-mll抑制剂 |
| WO2026035866A1 (en) | 2024-08-07 | 2026-02-12 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with a lag-3 inhibitor and a pd-1 inhibitor |
| KR20260116273A (ko) | 2024-09-20 | 2026-07-28 | 파라곤 테라퓨틱스, 인크. | Pd-1 결합 단백질, vegf 및 pd-1 이중특이적 결합 단백질, 조성물 및 사용 방법 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| WO2000032634A1 (en) | 1998-12-01 | 2000-06-08 | Protein Design Labs, Inc. | Humanized antibodies to gamma-interferon |
| DE60334303D1 (de) | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| WO2012135408A1 (en) | 2011-03-31 | 2012-10-04 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments |
| BR112014002353B1 (pt) | 2011-08-01 | 2022-09-27 | Genentech, Inc | Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| RS64268B1 (sr) * | 2013-09-20 | 2023-07-31 | Bristol Myers Squibb Co | Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora |
| WO2016011357A1 (en) * | 2014-07-18 | 2016-01-21 | Advaxis, Inc. | Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer |
| JO3663B1 (ar) * | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| US20170097333A1 (en) * | 2015-09-28 | 2017-04-06 | Merck Sharp & Dohme Corp. | Cell based assay to measure the t-cell stimulating capacity of anti-lag3 antibodies and other agents |
| TWI756187B (zh) * | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗lag3抗體及其用途 |
| US10613092B2 (en) * | 2016-04-01 | 2020-04-07 | Agilent Technologies, Inc. | Scoring methods for anti-PD therapy eligibility and compositions for performing same |
| KR102976378B1 (ko) * | 2016-06-03 | 2026-06-11 | 브리스톨-마이어스 스큅 컴퍼니 | 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도 |
| WO2019148412A1 (en) * | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
-
2019
- 2019-09-09 AU AU2019337547A patent/AU2019337547A1/en not_active Abandoned
- 2019-09-09 US US17/274,531 patent/US20210317214A1/en not_active Abandoned
- 2019-09-09 JP JP2021513868A patent/JP7470105B2/ja active Active
- 2019-09-09 CA CA3111066A patent/CA3111066A1/en active Pending
- 2019-09-09 WO PCT/US2019/050122 patent/WO2020055702A1/en not_active Ceased
- 2019-09-09 EP EP19859611.6A patent/EP3849606A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017524715A5 (cg-RX-API-DMAC7.html) | ||
| JP2024037894A5 (cg-RX-API-DMAC7.html) | ||
| JP2019519499A5 (cg-RX-API-DMAC7.html) | ||
| JP2018508483A5 (cg-RX-API-DMAC7.html) | ||
| FI3799885T3 (fi) | Lymfosyyttien estoreittien neutralointi | |
| MX2021011500A (es) | Anticuerpos multiespecificos egfr x cd28. | |
| IL318482A (en) | Pd-1 inhibitor for use in a method of treating skin cancer | |
| RU2014147867A (ru) | Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов | |
| JP2018070648A5 (cg-RX-API-DMAC7.html) | ||
| JP2019515008A5 (cg-RX-API-DMAC7.html) | ||
| HRP20231156T1 (hr) | Kombinacija anti-pd-1 antitijela i bispecifičnih anti-cd20/anti-cd3 antitijela za liječenje raka | |
| IL253462B (en) | Cancer treatment with monoclonal antibodies against latency-associated peptide | |
| JP2017535257A5 (cg-RX-API-DMAC7.html) | ||
| JP2020508317A5 (cg-RX-API-DMAC7.html) | ||
| JP2022512750A5 (cg-RX-API-DMAC7.html) | ||
| JP2016537383A5 (cg-RX-API-DMAC7.html) | ||
| JP2018518454A5 (cg-RX-API-DMAC7.html) | ||
| RU2018105846A (ru) | Комбинация антагониста pd-1 с ингибитором egfr | |
| JP2018522887A5 (cg-RX-API-DMAC7.html) | ||
| MX2020008446A (es) | Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4. | |
| WO2015200806A3 (en) | Humanized anti-tau antibodies | |
| RU2011116112A (ru) | Биспецифические анти-egfr/анти-igf-1r антитела | |
| PE20191759A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| JP2019524701A5 (cg-RX-API-DMAC7.html) | ||
| JP2022512851A5 (cg-RX-API-DMAC7.html) |